

Perspectives to the COVID-19 Immunopathology and Vaccine Status

Shyamapada Mandal

ABSTRACT: The ongoing coronavirus disease 2019 (COVID-19) pandemic, since its first emergence in China in December 2019 from SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) infection, caused more than 100 million people sick with 21.66 lakhs deaths globally, as of January 28, 2021. The highly infectious Betacoronavirus, SARS-CoV-2, replicates in the upper respiratory system at the disease initial stage (causing mild or asymptomatic COVID-19 in most cases), followed by immunopathological stage of inflammatory response to SARS-CoV-2 infection causing severe/critical COVID-19 with cytokine storm (a stage with substantial elevation of serum pro-inflammatory cytokines levels) and ARDS (acute respiratory

distress syndrome) and multiple organ failure (majorly lungs, as well as heart, liver and kidney). However, no specific drug or vaccine is available to effectively combat the COVID-19 pandemic that devastated the most vulnerable (people of old age, or with medical conditions). Vaccine is therefore urgently required to prevent SARS-CoV-2 transmission, and deaths due to COVID-19. This communication thus stands for analysis (based on the available published information) with an update of the vaccines (including the S glycoprotein targeted vaccines) that are in the pipeline of rapid pace of COVID-19 vaccine development. .

Biography:-

Dr. Shyamapada Mandal, Professor, Department of Zoology, University of Gour Banga, India, is interested on infectious diseases, probiotics, and genomics and bioinformatics research. He did pre-PhD, PhD, and post-PhD research under the guidance of Professor Nishith Kumar Pal at Calcutta School of Tropical Medicine, India. He has published 115 articles with 8 book chapters. He is life member of IAMM and IASR, India, and fellow member of SASS, India. Eight national academic and research awards have been conferred to him. He has guided 52 post graduate students; supervised three MPhil and three PhD students, and supervising 6 PhD students. Professor Mandal is among the world's top 2% scientists as per the survey of the Stanford University, published in PLOS (Public Library of Science) Biology (October, 2020).

References

1. Mandal, Manisha & Mandal, Shyamapada. (2021). Detection of transmission change points during unlock-3 and unlock-4 measures controlling COVID-19 in India. *Journal of Drug Delivery and Therapeutics*. 11. 76-86. 10.22270/jddt.v11i2.4600.
2. Mandal, Manisha & Mandal, Shyamapada. (2021). Bioinformatic Approaches for Identification of Potential Repurposable Drugs in COVID-19. *Journal of Drug Delivery and Therapeutics*. 11. 13-22. 10.22270/jddt.v11i1.447

Citation: Shyamapada Mandal; *Clinical Microbiology and Infectious Diseases; Microbiology* 2021; April 28, 2021; Dubai, UAEUAE

Laboratory of Microbiology and Experimental Medicine, Department of Zoology, University of Gour Banga, India



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com